MS SB2731

Establishes an eight-member Ad Hoc Committee to study issues related to pharmacist substitution of interchangeable biological products for prescribed products.

Committee composition includes the Chairmen of Senate Public Health and Welfare and House Public Health and Human Services committees as Co-Chairmen, three Senate members appointed by the Lieutenant Governor, and three House members appointed by the Speaker.

Defines key terms including "biological product," "biosimilar," and "interchangeable" by reference to federal FDA standards and the Orange Book therapeutic equivalence evaluations.

Committee shall receive testimony and information about prescription biosimilar substitution and FDA-determined interchangeable biological products, with administrative support provided by the State Board of Pharmacy.

Committee must issue a final report with legislative recommendations to the Legislature by January 1, 2015, and shall dissolve upon submission of its report; effective July 1, 2014.